u/hugo_bergstrom

the tendon claims are the most repeated and the least evidenced

That claim traces back to a single preclinical paper that says something considerably narrower.

if 7.5 is working, 10 is not automatically better

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other.

Batch number and date of analysis, are both on there?

biopsy-confirmed is not the same as imaging-suggested

Same view — reporting the gradient is what makes a result checkable rather than merely stated.

Correcting my own comment: the shortage status changed in the interim, so the arrangement I described no longer applies.

503A or 503B — do you know which?

The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.

Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.

25kg over 79 weeks, never went past 10mg, and sulphur burps stayed mild the whole way. Posting because the loud threads are all 15mg.

Careful. A four-week stall is inside normal variation and treating it as failure is how people escalate for no reason.

dual agonist, so the GIP arm is doing something the sema threads will not tell you about

Research-use-only material is not approved for human use, so anything in this thread about how a compounded or research vial "should" behave is a chemistry discussion, not a dosing one.

Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.

Careful — "the metadata looks odd" is a reason to ask a question, not a conclusion. Re-issues are ordinary.

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

dual agonist, so the GIP arm is doing something the sema threads will not tell you about

preclinical enthusiasm is not clinical evidence

The escalation schedule in the trials existed to keep people on the drug. It is a tolerability ramp, and it is why the label reads the way it does.

Same conditions each time for the weigh-in?

a log is not a plan and it is not advice for anybody else

Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

staying at 2.4mg for an extra month is a legitimate plan

Yes — and the reason to ask for the whole page is that the interesting parts are the ones people crop out to fit a screenshot.

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.

Same view — reporting the gradient is what makes a result checkable rather than merely stated.

Agreed. The dry powder is the robust state; it is the solution that needs the care.

What wavelength, and what was the gradient?

Sent a vial to Medutest because there was nothing on file. 99.6% against a claimed 99.0%. First entry for this compound in my own log.

a mean is not a promise

hold the dose that works, the ladder is not a leaderboard

Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.

Powder or already in solution?

Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.